Belite Bio, INC (BLTE) — 6-K Filings

6-K Filings (23)

• 6-K Filing — Mar 31, 2026
• 6-K Filing — Dec 2, 2025
• Belite Bio's Tinlarebant Shows Promise in Stargardt Disease Trial — Dec 1, 2025 Risk: medium
  On December 1, 2025, Belite Bio, Inc. announced positive topline results from its pivotal global Phase 3 DRAGON trial for tinlarebant in adolescents with Starga
• 6-K Filing — Nov 10, 2025
• Belite Bio Secures PIPE Financing — Sep 8, 2025 Risk: medium
  On September 8, 2025, Belite Bio, Inc. announced a private placement in public equity (PIPE) financing. The company entered into Securities Purchase Agreements
• Belite Bio Reports Q2 2025 Financials and Corporate Update — Aug 11, 2025 Risk: low
  Belite Bio, Inc. announced its second quarter 2025 financial results and provided a corporate update via a press release on August 11, 2025. The company is a fo
• Belite Bio Announces Registered Direct Offering — Aug 7, 2025 Risk: medium
  On August 6, 2025, Belite Bio, Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering. The offering i
• Belite Bio Completes Enrollment in Geographic Atrophy Trial — Jul 2, 2025 Risk: medium
  On July 2, 2025, Belite Bio, Inc. announced the completion of patient enrollment in its pivotal global Phase 3 PHOENIX trial. This trial is evaluating the oral
• Belite Bio's Tinlarebant Gets FDA Breakthrough Therapy Designation — May 21, 2025 Risk: medium
  On May 21, 2025, Belite Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its drug candidate,
• Belite Bio Reports Q1 2025 Results and Corporate Update — May 14, 2025 Risk: low
  Belite Bio, Inc. announced its first-quarter 2025 financial results and provided a corporate update via a press release on May 13, 2025. The company is a foreig
• Belite Bio Shareholders Approve All Proposed Resolutions — Apr 15, 2025 Risk: low
  Belite Bio, Inc. announced that all proposed resolutions from its March 18, 2025 Notice of Annual General Meeting were passed at the shareholder meeting held on
• Belite Bio Changes Auditors to Deloitte & Touche — Mar 28, 2025 Risk: low
  Belite Bio, Inc. announced on March 28, 2025, the dismissal of its former auditor, Marcum Asia CPAs LLP. The company has appointed Deloitte & Touche as its succ
• Belite Bio Announces 2025 Annual Shareholder Meeting Materials — Mar 18, 2025 Risk: low
  Belite Bio, Inc. announced on March 18, 2025, that it has made materials available to shareholders in connection with its 2025 annual general meeting. These mat
• Belite Bio Reports Q4 & FY 2024 Results — Mar 17, 2025 Risk: low
  Belite Bio, Inc. announced its fourth quarter and full-year 2024 financial results on March 17, 2025. The company also provided a corporate update alongside the
• Belite Bio Releases Interim Phase 3 Stargardt Trial Data — Feb 27, 2025 Risk: medium
  Belite Bio, Inc. announced on February 26, 2025, interim analysis results from its pivotal global Phase 3 DRAGON trial for tinlarebant in adolescent Stargardt d
• Belite Bio Prices $1M Direct Offering of ADSs and Warrants — Feb 6, 2025 Risk: medium
  On February 5, 2025, Belite Bio, Inc. entered into a securities purchase agreement for a registered direct offering of 258,309 American Depositary Shares (ADSs)
• Belite Bio Files November 2024 6-K Report — Nov 12, 2024 Risk: low
  Belite Bio, Inc. filed a Form 6-K on November 12, 2024, reporting for the month of November 2024. The filing is a report of a foreign private issuer pursuant to
• Belite Bio Files Form 6-K for November 2024 — Nov 4, 2024 Risk: low
  On November 3, 2024, Belite Bio, Inc. entered into an inducement offer letter agreement. This filing is a Form 6-K report for the month of November 2024, indica
• Belite Bio Appoints New Chief Medical Officer — Sep 3, 2024 Risk: low
  Belite Bio, Inc. announced on September 1, 2024, the appointment of Dr. Hendrik P. N. Scholl, MD, MA, as its new Chief Medical Officer. This appointment is deta
• Belite Bio Files August 2024 6-K Report — Aug 9, 2024 Risk: low
  Belite Bio, Inc. filed a Form 6-K on August 9, 2024, reporting its activities for the month of August 2024. The filing is a report of a foreign private issuer p
• Belite Bio Files 6-K Report — May 14, 2024 Risk: low
  Belite Bio, Inc. filed a Form 6-K on May 14, 2024, reporting on its activities for the month of May 2024. The filing is a report of a foreign private issuer pur
• Belite Bio Prices $3M Direct Offering of ADSs and Warrants — Apr 26, 2024 Risk: medium
  On April 25, 2024, Belite Bio, Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering. The company wi
• Belite Bio Submits Tinlarebant Trial to Japan's PMDA — Mar 22, 2024 Risk: medium
  On March 22, 2024, Belite Bio, Inc. announced the submission of its tinlarebant clinical trial application to Japan's Pharmaceuticals and Medical Devices Agency

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX